Is Cancer Cell a Good Journal? Impact Factor, Comparison, and Fit Verdict

Cancer Cell is part of the Cell Press family, alongside Cell, Molecular Cell, Developmental Cell, and others. This matters because Cell Press journals share a distinctive editorial culture: professional in-house editors who manage every paper from submission through acceptance, and a negotiated revision model that sets them apart from society journals or Nature titles.

Cell Press launched Cancer Cell in 2002 to carve out a dedicated home for cancer biology that didn't fit the broader scope of Cell itself. The journal quickly established itself as the place where cancer researchers publish work that moves the whole field, not just one tumor type or one pathway.

The in-house editor model is worth understanding. Cancer Cell's editors are full-time professionals with deep cancer biology training. They're not running their own labs. They're reading manuscripts all week, attending cancer conferences, and tracking the field's open questions. This means the desk screen is fast, informed, and hard to fake. A cover letter claiming "broad impact" without the data to back it won't survive.

Cancer Cell demands systems-level thinking about cancer. The editors are not simply looking for technically strong oncology papers. They want manuscripts that shift how cancer researchers interpret disease biology, therapy, or tumor behavior at a conceptual level.

This means the journal is comfortable with tumor microenvironment papers, translational studies connecting patient observation to mechanism, and systems-level cancer biology. It is uncomfortable with pathway extensions that add detail without changing the framework, single-target studies without broader disease logic, and papers whose "cancer relevance" is asserted in the discussion rather than demonstrated in the data.

The 182-day timeline and negotiated revision process are real. Cancer Cell editors discuss what additional experiments would make the disease consequence airtight. Authors should expect a revision that involves new data, not just rewriting. If the revision letter says "demonstrate the in vivo consequence," that means generate the data, not add a sentence.

A Cancer Cell publication carries weight far beyond the impact factor number. In cancer biology hiring and tenure decisions, a Cancer Cell paper signals that the work was evaluated by Cell Press's notoriously demanding editorial team and survived their negotiated revision process. It tells a hiring committee that the work changes how cancer is understood, not just that it's technically impressive.

For early-career researchers, the distinction between Cancer Cell and a society journal like Cancer Research can shape a job search. For established PIs, it's the difference between "good lab" and "lab that defines a subfield." That said, Cancer Cell's 182-day timeline and demanding revision process make it a risky bet when tenure clocks are ticking. A strong paper at Cancer Discovery or Nature Cancer, published six months earlier, may serve a career better than a Cancer Cell revision that drags into a second round.

Cancer Cell editors are in-house Cell Press professionals who specialize in cancer biology. They read for systems-level thinking: does this paper change how we understand cancer as a disease, or does it add another node to an existing pathway map?

The negotiated revision is particularly demanding at Cancer Cell. Editors often request that authors demonstrate disease consequence more directly, which can mean additional patient data, in vivo validation, or therapeutic relevance experiments. Authors who lack access to clinical samples or relevant animal models should think carefully before submitting.

In our pre-submission review work with manuscripts targeting Cancer Cell, three patterns generate the most consistent early editor pushback.

The cancer consequence arrives too late. Editors at Cancer Cell are screening for disease logic from the first figures, not for a generic cell-biology story that gets a cancer panel at the end. When the tumor model, patient sample, or therapeutic consequence only appears in the last section, the paper usually reads like Cell, Molecular Cell, or a specialty biology journal submission that was retrofitted for oncology.

The mechanism is suggestive but not closed. Cancer Cell is willing to back ambitious stories, but not when the central driver is still inferred from correlation, one perturbation, or one model. The manuscripts that stall here usually have a striking phenotype, then lose force because the rescue logic, orthogonal validation, or in vivo consequence is still incomplete.

The translational claim outruns the evidence package. Cancer Cell is comfortable with translational framing, but only when the paper shows why the mechanistic result matters for tumors, therapy response, immune context, or patient stratification. If the abstract promises therapeutic relevance and the data stop at pathway logic, editors tend to route the paper toward a lower-risk sister venue.

Is Cancer Cell a good journal?

Yes. Cancer Cell is the flagship cancer journal from Cell Press with a 2024 impact factor of 44.5 and Q1 ranking in Oncology and Cell Biology. It publishes cancer biology that changes how the field thinks about disease mechanisms, not cell biology that happens to use cancer models.

What is Cancer Cell's acceptance rate?

Cancer Cell accepts approximately 5-8% of submissions. The median time from submission to acceptance is about 182 days, reflecting the negotiated revision process where editors discuss additional experiments rather than prescribing a checklist.

Is Cancer Cell peer reviewed?

Yes. Cancer Cell uses rigorous peer review managed by professional in-house Cell Press editors with deep cancer biology expertise. The negotiated revision model means revisions are a conversation, not a prescription.

What is Cancer Cell's impact factor?

Cancer Cell has a 2024 JCR impact factor of 44.5. It is ranked Q1 in both Oncology and Cell Biology, making it one of the highest-impact dedicated cancer journals.

How does Cancer Cell compare to Nature Cancer?

Cancer Cell (IF 44.5) demands deeper mechanistic closure than Nature Cancer (IF 28.5). Nature Cancer is more flexible about translational framing and doesn't require the same degree of resolved mechanism. Cancer Cell wants the mechanistic story to be airtight; Nature Cancer will consider strong translational relevance with less complete mechanism.

What is the difference between Cancer Cell and JCO?

Cancer Cell publishes cancer biology mechanism papers. JCO publishes clinical oncology, trials, outcomes, clinical practice. There is almost no overlap. If the paper's value is clinical results rather than biological mechanism, JCO is the right journal.